Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
The expansion includes a larger technical and service team and increased local procurement
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The update promises to revolutionize laboratory workflows by optimizing resources
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
The new facility is expected to generate 500-600 new jobs in the region
The state-of-the-art facility is expected to be commissioned over the next three years
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
